Abrahamson M
Department of Clinical Chemistry, University of Lund, University Hospital, Sweden.
Scand J Clin Lab Invest Suppl. 1996;226:47-56.
The aim of the project has been to elucidate molecular events leading to amyloidosis in Hereditary Cystatin C Amyloid Angiopathy (HCCAA) patients, to enable simple diagnosis of the disease and with the ultimate goal to understand the amyloid formation process in detail, in order to develop inhibitors to the process. At the DNA level, a point mutation segregating with HCCAA was identified in the cystatin C gene on chromosome 20, after basic characterization of cDNA and gene for the wildtype protein. The mutation results in the amino acid substitution Leu-68-Gin (L68Q) and abolishes a recognition site for Alu I. This information was used to design a PCR based assay for simple and rapid mutation detection in DNA from blood samples to allow routine diagnosis of HCCAA. Studies at the protein level, allowed through E. coli expression of wildtype and L68Q mutated cystatin C genes, revealed that both protein variants effectively inhibit the cysteine proteinase cathepsin B (equilibrium constants for dissociation: 0.4 and 0.3 nM, respectively), but differ considerably in their tendency to dimerize and form aggregates. The initial dimerization of L68Q-cystatin C results in complete loss of biological activity and is highly temperature-dependent, with a rise in incubation temperature from 37 to 40 degrees C resulting in a 150% increase in dimerization rate. This result might be of clinical relevance, since medical intervention to abort febrile periods of carriers of the disease trait may reduce the in vivo formation of L68Q-cystatin C aggregates. The three-dimensional structure of normal cystatin C, crystallized in a complex with cathepsin B, was elucidated by X-ray analysis and subsequent refinement of the structure to 3.0 A resolution. Besides pinpointing the cystatin C structures resulting in efficient target enzyme inhibition, the results demonstrated that the Leu-68 residue is buried in the hydrophobic core of the protein. Studies of the three-dimensional solution structure of wildtype cystatin C by NMR spectroscopy revealed that cystatin C dimers can be formed as a result of slight, localized structural changes under conditions preceding complete defolding and denaturation of the protein. Dimers of L68Q-cystatin C are likely similar but are formed at temperatures nearly 30 degrees C lower than needed for the wildtype protein, indicating that the Leu-68-Gln substitution lowers the transition temperature for unfolding. Thus, the results presented suggest that cystatin C provides a system where decreased stability of a mutant protein correlates with its amyloidogenic nature. The NMR results furthermore imply that the hydrophobic proteinase-binding region of cystatin C is directly involved in dimer formation and that compounds designed to interact with this region could serve as inhibitors to the dimerization, and likely also the subsequent amyloid formation process, of cystatin C in HCCAA patients.
该项目的目标是阐明导致遗传性胱抑素C淀粉样血管病(HCCAA)患者发生淀粉样变性的分子事件,实现对该疾病的简易诊断,并最终详细了解淀粉样蛋白形成过程,以便开发针对该过程的抑制剂。在DNA水平上,在对野生型蛋白的cDNA和基因进行基本特征分析后,在20号染色体上的胱抑素C基因中鉴定出一个与HCCAA共分离的点突变。该突变导致氨基酸替换Leu-68-Gln(L68Q),并消除了Alu I的识别位点。利用这一信息设计了一种基于PCR的检测方法,用于从血液样本DNA中简单快速地检测突变,以实现HCCAA的常规诊断。通过大肠杆菌表达野生型和L68Q突变的胱抑素C基因进行的蛋白质水平研究表明,两种蛋白质变体均能有效抑制半胱氨酸蛋白酶组织蛋白酶B(解离平衡常数分别为0.4和0.3 nM),但在二聚化和形成聚集体的倾向方面有很大差异。L68Q-胱抑素C的初始二聚化导致生物活性完全丧失,且高度依赖温度,孵育温度从37℃升高到40℃会导致二聚化速率增加150%。这一结果可能具有临床意义,因为对具有疾病特征携带者发热期进行医疗干预可能会减少体内L68Q-胱抑素C聚集体的形成。通过X射线分析并随后将结构精修至3.0 Å分辨率,阐明了与组织蛋白酶B形成复合物结晶的正常胱抑素C的三维结构。除了确定导致有效抑制靶酶的胱抑素C结构外,结果还表明Leu-68残基埋藏在蛋白质的疏水核心中。通过核磁共振光谱对野生型胱抑素C的三维溶液结构进行研究表明,在蛋白质完全去折叠和变性之前的条件下,由于轻微的局部结构变化,胱抑素C可以形成二聚体。L68Q-胱抑素C的二聚体可能相似,但形成温度比野生型蛋白所需温度低近30℃,这表明Leu-68-Gln替换降低了去折叠的转变温度。因此,所呈现的结果表明,胱抑素C提供了一个系统,其中突变蛋白稳定性的降低与其淀粉样变性性质相关。核磁共振结果还暗示,胱抑素C的疏水蛋白酶结合区域直接参与二聚体形成,设计与该区域相互作用的化合物可作为胱抑素C在HCCAA患者中二聚化以及随后淀粉样蛋白形成过程的抑制剂。